New signature predicts chemotherapy outcomes in pancreatic cancer

A predictive and prognostic signature, named chemoresist, effectively identifies pancreatic ductal adenocarcinoma patients likely to benefit from adjuvant chemotherapy. In a multicenter study involving 551 patients, the chemoresist classifier demonstrated significant survival differences between high- and low-score patients, outperforming traditional TNM staging. It achieved higher predictive accuracy for two-year overall survival (AUC 0.788 vs. 0.636, p<0.001) and aided in discerning chemotherapy responses, thus providing a valuable tool for personalized treatment strategies.